Abbott Laboratories

Abbott has generally demonstrated prudent use of capital. In recent years it invested heavily in R&D (over $2.5B/year) and capacity (new manufacturing lines for devices and formula) to fuel growth. Capex has been modest ($2.2B in 2024) relative to cash flows, reflecting an asset-light product model. Major acquisitions (e.g. $25B for St.

Jude, smaller deals in diagnostics) have been executed at reasonable prices and with clear strategic fit. Management has also used free cash flow to reward shareholders: Abbott currently pays a dividend yielding 3–4%, with a track record of annual hikes.

Share repurchases ($1.3B in 2024) have shrunk the float slowly (offsetting dilution from stock comp), which is positive. We note stock-based compensation ($0.7B in 2024)) is not trivial but Abbott’s repurchases roughly match option issuance, keeping net dilution low.

Overall returns on invested capital have been high (around 18–20% recent global ROIC). We give strong marks (80) – Abbott reinvests in its core businesses and returns capital balanceably. One minor concern is reliance on dividend; the payout ratio (on depressed net income) is moderate, and we’d prefer more buyback at cheaper valuations.

But there’s no aggressive debt for buybacks. In sum, capital allocation is disciplined and shareholder-friendly.